AVENUE THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Avenue Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q3 2024.
  • Avenue Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$3.08M, a 685% decline year-over-year.
  • Avenue Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$3.55M, a 4.8% increase from 2021.
  • Avenue Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$3.73M, a 27.6% increase from 2020.
  • Avenue Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$5.15M, a 80.1% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$3.08M -$3.6M -685% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$2.69M +$1.32M +32.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q3 2023 $526K +$1.19M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$4.01M -$3.4M -563% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q4 2022 -$3.55M $575K +$1.49M Oct 1, 2022 Dec 31, 2022 10-K 2023-03-31
Q3 2022 -$5.04M -$662K +$209K +24% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$5.25M -$604K +$345K +36.4% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-15
Q1 2022 -$5.59M -$2.86M -$1.86M -187% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q4 2021 -$3.73M -$913K +$80K +8.06% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$3.81M -$871K +$157K +15.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$3.97M -$949K +$939K +49.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$4.91M -$998K +$244K +19.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$5.15M -$993K +$4.42M +81.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-25
Q3 2020 -$9.57M -$1.03M +$1.21M +54.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$10.8M -$1.89M +$5.09M +73% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$15.9M -$1.24M +$10M +89% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$25.9M -$5.42M -$1.5M -38.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$24.4M -$2.24M +$353K +13.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$24.8M -$6.98M -$2.33M -49.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$22.4M -$11.3M -$892K -8.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$21.5M -$3.92M +$2.32M +37.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 -$23.9M -$2.6M +$353K +12% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$24.2M -$4.66M -$2.25M -93.6% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$22M -$10.4M -$9.72M -1470% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q4 2017 -$12.3M -$6.24M -$5.43M -666% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-01
Q3 2017 -$6.83M -$2.95M -$2.4M -442% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$4.43M -$2.41M -$1.64M -212% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$2.79M -$661K +$386K +36.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 -$3.18M -$815K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$544K Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$771K Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$1.05M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.